Compare Baker Hughes Co (BKR) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Baker Hughes Co vs State Street SPDR S&P Biotech ETF — how do they compare? Baker Hughes Co trades at $64.89 (market cap $64.34B), while State Street SPDR S&P Biotech ETF trades at $159.3. The key difference: Baker Hughes Co pays a 1.42% dividend while State Street SPDR S&P Biotech ETF pays none, and State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, Baker Hughes Co nearer its low. Which is the better fit depends on your goals.
| BKR | XBI | |
|---|---|---|
Market Cap | $64.34B | — |
Sector | Energy | Broad Market / Factor |
52-Week High | $69.67 | $164.28 |
52-Week Low | $42.51 | $86.92 |
Enterprise Value | $64.86B | — |
Dividend Yield | 1.42% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Baker Hughes (BKR) trades at $64.94, up 1.35% on the day, with a bullish technical signal and strong earnings beats in recent quarters. The company demonstrates robust fundamentals with a P/E of 20.84, ROE of 16.47%, and positive cash flow trends. Recent news highlights major contract wins in subsea systems and LNG technology, signaling strong demand for its energy infrastructure solutions.
The outlook for BKR is positive, supported by analyst consensus and operational strength, though risks include integration challenges from acquisitions and potential volatility in oil & gas spending. The stock presents an opportunity for growth investors seeking exposure to energy technology, with a consensus price target of $73.25 implying potential upside.
XBI trades at $159.15, up 0.71% with a bullish technical signal from moving averages. The biotech ETF shows strong momentum with a 17% monthly gain, driven by positive clinical data and M&A activity. Analyst coverage remains limited with a single hold rating, while institutional interest grows with recent $793,000 investment from Bay Colony Advisors.
Outlook remains positive given biotech sector resurgence, though elevated RSI suggests near-term overbought conditions. Key risks include sector volatility and regulatory uncertainty, but AI-driven drug discovery and strong pipeline developments provide growth catalysts for patient investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Baker Hughes Co
Baker Hughes is a global leader in oilfield services and oilfield equipment, with particularly strong presences in the artificial lift, specialty chemicals, and completions markets. The other half of its business focuses on industrial power generation, process solutions, and industrial asset management, with high exposure to the liquid natural gas market specifically, as well as broader industrials end markets.
Read more on BKR →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
